TY - JOUR T1 - Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. AU - Strollo,Rocky, AU - Ponchel,Frederique, AU - Malmström,Vivianne, AU - Rizzo,Paola, AU - Bombardieri,Michele, AU - Wenham,Claire Y, AU - Landy,Rebecca, AU - Perret,David, AU - Watt,Fiona, AU - Corrigall,Valerie M, AU - Winyard,Paul G, AU - Pozzilli,Paolo, AU - Conaghan,Philip G, AU - Panayi,Gabriel S, AU - Klareskog,Lars, AU - Emery,Paul, AU - Nissim,Ahuva, PY - 2012/08/01/received PY - 2013/04/02/accepted PY - 2013/4/12/entrez PY - 2013/4/12/pubmed PY - 2013/9/5/medline SP - 1702 EP - 12 JF - Arthritis and rheumatism JO - Arthritis Rheum VL - 65 IS - 7 N2 - OBJECTIVE: Type II collagen (CII) posttranslationally modified by reactive oxygen species (ROS-CII) that are present in the inflamed joint is an autoantigen in rheumatoid arthritis (RA). The aim of this study was to investigate the potential use of anti-ROS-CII autoantibodies as a biomarker of RA. METHODS: CII was exposed to oxidants that are present in the rheumatoid joint. Autoreactivity to ROS-CII was assessed by enzyme-linked immunosorbent assays in synovial fluid (SF) and serum samples obtained from patients during various phases of RA. This group included disease-modifying antirheumatic drug (DMARD)-naive patients with early RA (n = 85 serum samples) and patients with established RA (n = 80 serum and 50 SF samples), who were categorized as either DMARD responders or DMARD nonresponders. Control subjects included anti-citrullinated protein antibody (ACPA)-positive patients with arthralgia (n = 58 serum samples), patients with osteoarthritis (OA; n = 49 serum and 52 SF samples), and healthy individuals (n = 51 serum samples). RESULTS: Reactivity to ROS-CII among DMARD-naive patients with early RA was significantly higher than that among patients with ACPA-positive arthralgia, patients with OA, and healthy control subjects (P < 0.0001), with 92.9% of serum samples from the patients with early RA binding to anti-ROS-II. There was no significant difference in anti-ROS-CII reactivity between ACPA-positive and ACPA-negative patients with RA, with 93.8% and 91.6% of serum samples, respectively, binding to ROS-CII. The sensitivity and specificity of binding to ROS-CII in patients with early RA were 92% and 98%, respectively. Among patients with established RA, serum reactivity in DMARD nonresponders was significantly higher than that in DMARD responders (P < 0.01); 58.3% of serum samples from nonresponders and 7.6% of serum samples from responders bound to HOCl-ROS, while the respective values for SF were 70% and 60%. In patients with longstanding RA, autoreactivity to ROS-CII changed longitudinally. CONCLUSION: Autoantibodies to ROS-CII have the potential to become diagnostic biomarkers of RA. SN - 1529-0131 UR - https://www.unboundmedicine.com/medline/citation/23575908/Autoantibodies_to_posttranslationally_modified_type_II_collagen_as_potential_biomarkers_for_rheumatoid_arthritis_ L2 - https://doi.org/10.1002/art.37964 DB - PRIME DP - Unbound Medicine ER -